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InsOBJECTIVES The purposes of this study were to determine why chronic obstructive pulmonary disease (COPD) is
associated with heart failure (HF). Specific objectives included whether COPD is associated with myocardial fibrosis,
whether myocardial fibrosis is associated with hospitalization for HF and death in COPD, and whether COPD and smoking
are associated with myocardial inflammation.
BACKGROUND COPD is associated with HF independent of shared risk factors. The underlying pathophysiological
mechanism is unknown.
METHODS A prospective, multicenter, longitudinal cohort study of 572 patients undergoing cardiac magnetic resonance
(CMR), including 450 patients with COPD and 122 age- and sex-matched patients with a median: 726 days (interquartile
range: 492 to 1,160 days) follow-up. Multivariate analysis was used to examine the relationship between COPD and
myocardial fibrosis, measured using cardiac magnetic resonance (CMR). Cox regression analysis was used to examine the
relationship between myocardial fibrosis and outcomes; the primary endpoint was composite of hospitalizations for HF or
all-cause mortality; secondary endpoints included hospitalizations for HF and all-cause mortality. Fifteen patients with
COPD, 15 current smokers, and 15 healthy volunteers underwent evaluation for myocardial inflammation, including ul-
trasmall superparamagnetic particles of iron oxide CMR.
RESULTS COPD was independently associated with myocardial fibrosis (p < 0.001). Myocardial fibrosis was indepen-
dently associated with the primary outcome (hazard ratio [HR]: 1.14; 95% confidence interval [CI]: 1.08 to 1.20;
p < 0.001), hospitalization for HF (HR: 1.25 [95% CI: 1.14 to 1.36]); p < 0.001), and all-cause mortality. Myocardial
fibrosis was associated with outcome measurements more strongly than any other variable. Acute and stable COPD were
associated with myocardial inflammation.
CONCLUSIONS The associations between COPD, myocardial inflammation and myocardial fibrosis, and the independent
prognostic value of myocardial fibrosis elucidate a potential pathophysiological link between COPD and HF.
(J Am Coll Cardiol Img 2021;-:-–-) © 2021 The Authors. Published by Elsevier on behalf of the American College of
Cardiology Foundation. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).N 1936-878X https://doi.org/10.1016/j.jcmg.2021.03.026
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ABBR EV I A T I ON S
AND ACRONYMS
CI = confidence interval
COPD = chronic obstructive
pulmonary disease
ECV = extracellular volume
FEV1 = forced expiratory
volume in 1 s
FVC = forced vital capacity
HF = heart failure
HR = hazard ratio
LV = left ventricular
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C hronic obstructive pulmonary dis-ease (COPD) is associated with leftventricular heart failure (HF), inde-
pendent of shared risk factors, and HF inde-
pendently contributes to mortality in
patients with COPD (1).
The pathophysiological mechanisms un-
derlying the association remain unclear.
Myocardial fibrosis, driven by myocardial
inflammation occurring as part of systemic
inflammation, is a widely held hypothesis,
but evidence for this is lacking, and other
mechanisms have been proposed (2–4).
Elucidating the underlying pathophysiology
would enable improved risk stratification
and development and evaluation of thera-
pies targeting the pathophysiology.This multicenter study aimed to determine why
COPD is associated with HF. Specifically, it aimed to
answer the following questions. 1) Is COPD associated
with myocardial fibrosis? 2) Is myocardial fibrosis
associated with hospitalization for HF and death in
patients with COPD? and 3) Are COPD and smoking
associated with myocardial inflammation?
METHODS
The study was approved by an ethics committee at
each site, and all participants provided written
informed consent.
PART 1. INVESTIGATION OF THE RELATIONSHIP
BETWEEN COPD AND MYOCARDIAL FIBROSIS, AND
THE RELATIONSHIP BETWEEN MYOCARDIAL
FIBROSIS AND OUTCOME IN COPD. Study design
and participants. A prospective, multicenter, longitu-
dinal cohort study was conducted in order to: 1)
evaluate the relationship between COPD and
myocardial fibrosis; and 2) to determine whetherof Pittsburgh, Pittsburgh, Pennsylvania, USA; fDivision of Infecti
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Consecutive adult patients undergoing clinical
cardiac magnetic resonance (CMR) at University of
Pittsburgh Medical Centre (UPMC) between June 2010
and April 2015, and at Manchester University NHS
Foundation Trust (MFT) between January 2015 and
July 2018, were prospectively recruited. Consecutive
patients with diagnoses of stable COPD, as deter-
mined by their medical record, were identified.
Randomly selected age- and sex-matched patients
without COPD were identified as a control population.
Exclusion criteria included amyloidosis, hypertrophic
cardiomyopathy, acute myocardial infarction,
myocarditis, takotsubo cardiomyopathy, and com-
plex congenital heart disease.
STUDY PROCEDURES. Cardiac CMR was performed
using 3 scanners (1.5-T Avanto model, Siemens,
Munich, Germany; 1.5-T Espree model, Siemens; and
3-T Skyra model, Siemens) and included steady-state
free precession cine imaging (standard long- and
short-axis views), basal and mid-left ventricular (LV)
short-axis T1 mapping (MOdified Look-Locker Inver-
sion Recovery [MOLLI]) pre- and post-gadolinium-
based contrast agent (0.15 to 0.20 mmol/kg gado-
terate meglumine [Dotarem], Guerbet, Princeton,
New Jersey) or 0.20 mmol/kg gadoteridol (Prohance,
Bracco Diagnostics, Milan, Italy) and late gadolinium
enhancement imaging. Hematocrit and estimated
glomerular filtration rate (eGFR) were measured on
the same day. Clinically available pulmonary function
tests were recorded.
CARDIAC CMR ANALYSIS. Volumetric analysis was
performed in accordance with current guidelines,
with papillary muscles included in measurement of
myocardial mass (5). Myocardial fibrosis was
measured using the extracellular volume (ECV)on, Immunity, and Respiratory Medicine, School of
cademic Health Science Centre, University of Man-
S Foundation Trust, Hazel Grove, Stockport, United
th, Bolton, United Kingdom; iRoyal Albert Edward
nited Kingdom; jTameside Hospital, Tameside and
d Kingdom; kTrafford General Hospital, Manchester
; lFairfield General Hospital, Pennine Acute Hospitals
al, East Cheshire NHS Trust, Macclesfield, Cheshire,
Kingdom; oNational Heart and Lung Institute, Im-
atrix Biology and Regenerative Medicine, Wellcome
ne and Health, Manchester Academic Health Science
es and animal welfare regulations of the authors’
t consent where appropriate. For more information,
h 17, 2021, accepted March 19, 2021.
TABLE 1 Participant Characteristics
COPD (n ¼ 450) Non–COPD (n ¼ 122) p Value
Demographics
Age, yrs 65 (58–72) 64 (57–72) 0.819
Males 290  64 79  65 1.000
Scanning details
Hospital MFT:UPMC 363:87 (81:19) 100:22 (82:18) 0.796
Scanner 1.5-T : 3-T 258:192 (57:43) 68:54 (56:44) 0.758
Comorbidities
Diabetes mellitus 111  25 17  14 0.014
Hypertension 236  52 52  42 0.066
Dyslipidemia 249  55 71  58 0.608
Atrial fibrillation 84  19 25  21 0.697
Coronary revascularizations 111  25 34  28 0.483
Current smoker 133  30 13  11 <0.001
Ever smoker 391  87 65  53 <0.001
BSA, m2 1.9 (1.7–2.1) 2.0 (1.8–2.2) 0.038
Laboratory and CMR findings
LV EDV/BSA, ml/m2 81 (64–102)* 84 (73–96) 0.093
LV ESV/BSA, ml/m2 35 (24–56)* 32 (24–45) 0.248
LVEF % 55 (44–65)* 60 (51–70) <0.001
LV mass/BSA, g/m2 63 (51–77)* 65 (53–75) 0.853
MI present 154  34† 44  36 1.000
RV EDV/BSA, ml/m2 39 (32–47)|| 40 (35–47)¶ 0.252
RV ESV/BSA, ml/m2 17 (13–23)|| 15 (13–19)¶ 0.227
RVEF % 56 (49–63)|| 62 (55–66)¶ <0.001
ECV % 28.0 (25.8–31.1)‡ 26.1 (23.7–28.8) <0.001
eGFR, ml/min/1.73 m2 78 (62–90)§ 79 (68–90) 0.633
Hematocrit % 41.3 (37.9–44.9)† 41.3 (39.2–44.4) 0.614
Values are median (interquartile range) or mean  SD or median (IQR) depending on distribution. *n ¼ 435;
†n ¼ 425; ‡n ¼ 393 (it was not possible to calculate ECV in 57 patients because the native or post–contrast T1
maps were not acquired or because same–day hematocrit was not available); §n ¼ 449; ||n ¼ 348; ¶n ¼ 100.
BSA ¼ body surface area; CMR ¼ cardiac magnetic resonance; COPD ¼ chronic obstructive pulmonary disease;
ECV ¼ extracellular volume; EDV ¼ end diastolic volume; EF ¼ ejection fraction; eGFR ¼ estimated glomerular
filtration rate; ESV ¼ end systolic volume; LV ¼ left ventricle; MFT ¼ Manchester University NHS Foundation
Trust; MI ¼ myocardial infarction; UPMC ¼ University of Pittsburgh Medical Centre.
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technique using the middle one-third of the LV short-
axis myocardium (6). Infarcted myocardium was
excluded from the ECV measurement while foci of
non-ischemic enhancement were included, according
to Society for Cardiovascular Magnetic Resonance
recommendations (7). CMR analysis was performed
blinded to outcome data but not blinded to the
presence or absence of COPD.
STUDY OUTCOMES. Data were managed using
Research Electronic Data Capture (REDCap) (8).
Baseline comorbidity data were determined from
primary and secondary care medical records.
The primary endpoint was a composite of first
hospitalization for HF after cardiac CMR or all-cause
mortality. The secondary endpoints were: 1) first
hospitalization for HF after cardiac CMR; and 2) all-
cause mortality. First hospitalization for HF was
recorded from primary and secondary care medical
records and determined independently by the clinical
team responsible for the patient’s care. Mortality
status for UPMC patients was ascertained by Social
Security Death Index queries and verified against
patients’ medical records. Mortality status for pa-
tients with MFT was ascertained from primary and
secondary care medical records.
PART 2. INVESTIGATION OF THE RELATIONSHIP BETWEEN
COPD AND MYOCARDIAL INFLAMMATION, AND SMOKING
AND MYOCARDIAL INFLAMMATION. Study design and
participants. A prospective observational study was
conducted in order to determine whether: 1) COPD;
and 2) smoking are associated with myocardial
inflammation.
Consecutive consenting patients with an acute
respiratory exacerbation of COPD, defined in accor-
dance with the Global Initiative for COPD (9), be-
tween October 2017 and November 2018, managed by
the clinical respiratory team at MFT, were prospec-
tively recruited. Patients were evaluated on 2 occa-
sions: 1) during the acute exacerbation, within
3 weeks of the onset of symptoms of the exacerbation
(“acute”); and 2) when stable, a minimum of 2 months
after the exacerbation (“stable”).
Consecutive consenting current smokers with a
smoking history of $10 pack-years and without a
diagnosis of COPD or significant airflow obstruction
(defined as the ratio of forced expiratory volume in 1
s [FEV1; l] to the forced vital capacity [FVC; l] >0.7)
were prospectively recruited through poster adver-
tisement. Age- and sex-matched healthy volunteers
(no cardiovascular symptoms, no history of medical
conditions, and normal electrocardiogram results)
were recruited by poster advertisement forcomparisons. Smokers and healthy volunteers un-
derwent 1 assessment.
Exclusion criteria included contraindication to
CMR; estimated glomerular filtration rate <50 ml/
min/1.73 m2; iron overload; absolute erythrocytosis or
polycythemia; hypotension; known HF; or previous
myocardial infarction.
STUDY PROCEDURES. Evaluation included labora-
tory measurements (blood count, renal function, liver
function, C-reactive protein, high-sensitivity
troponin I), spirometry and CMR. Briefly, the CMR
protocol included parametric mapping, dynamic
contrast-enhanced CMR, ultrasmall super-
paramagnetic particles of iron oxide (USPIO)-
enhanced CMR and late gadolinium-enhanced CMR.
CMR was performed before and at 48 and 73 h
following an infusion of USPIO (ferumoxytol, AMAG
TABLE 2 Univariate and Multivariate Associations With Myocardial Fibrosis, Measured Using Myocardial Extracellular Volume
Univariate Model (n ¼ 515†) Multivariate Model (n ¼ 514)
t Value B  SE p Value t Value B  SE p Value
Demographics
Age (per 1 yr increase) 0.28 0.01  0.02 0.784
Males 3.72 1.40  0.38 <0.001
BSA (per 0.01 m2 increase) 5.50 0.04  0.66 <0.001 3.83 0.02  0.01 <0.001
UPMC hospital 5.82 2.53  0.44 <0.001
Comorbidities
COPD 4.91 2.07  0.42 <0.001 3.25 1.15  0.35 0.001
Current smoker 5.00 2.06  0.41 <0.001 3.33 1.17  0.35 0.001
Ever smoker 3.81 1.71  0.45 <0.001
Diabetes mellitus 1.18 0.51  0.43 0.240
Hypertension 0.56 0.21  0.37 0.574
Dyslipidemia 2.98 1.09  0.37 0.003
Atrial fibrillation 1.08 0.50  0.46 0.282
Coronary revascularizations 3.73 1.57  0.42 <0.001 3.79 1.30  0.34 <0.001
Laboratory and CMR findings
LVEF (per 1% increase) 6.49 0.07  0.01 <0.001 7.49 0.07  0.01 <0.001
LV mass (per 1 g/m2 increase) 3.08 0.03  0.01 0.002
MI present 0.62 0.24  0.38 0.538
eGFR* 1.34 0.01  0.01 0.182 2.06 0.02  0.01 0.040
Hematocrit % 11.23 0.34  0.03 <0.001 12.49 0.35  0.03 <0.001
Values are mean  SD depending on distribution. *n ¼ 514, per 1 ml/min per 1.73 m2 increase. †n ¼ 515 consisting of 393 patients with COPD and 122 non–COPD patients, as
shown in Table 1.
CMR ¼ cardiac magnetic resonance; other abbreviations as in Table 1.
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Pharmaceuticals, Waltham, Massachusetts). Myocar-
dial R2* behavior over time and R2*:R1 ratio were
measured. USPIO are phagocytosed by active cardiac
macrophages and this protocol specifically identifies
myocardial inflammation (10). Supplemental Appen-
dix shows details of protocol and analysis.
STATISTICAL ANALYSIS. Part 1 was powered for a
multivariate linear regression analysis aimed at
determining the relationship between COPD and
myocardial fibrosis, measured using ECV. A total of
465 patients, including 365 patients with COPD and
100 age- and sex-matched patients without COPD,
provided the study with 90% power to detect an in-
crease in R2 after including the COPD variable in the
multivariate model of 1% or more, assuming an R2
value of the model prior to including COPD of 0.55. A
higher number of patients with COPD than antici-
pated were identified, thus the number of patients
without COPD included was increased proportion-
ately. Participants without COPD were selected using
proportional random sampling with subgroups
defined by 10-year age bands and sex from both sites
separately to ensure that the proportions of COPD to
age- and sex-matched patients without COPD from
each site were consistent.For Part 2, 15 patients with COPD were required to
detect an absolute minimum difference between
acute and stable scans, of 3 in terms of changes in
R2*:R1 ratio, with 80% power at a 5% significance
level (2-sided), assuming a SD of the within-patient
differences equal to 4.
Data were summarized using mean  SD or median
and interquartile range (IQR) and were compared
using Student’s t-tests or non-parametric equivalents
as appropriate. Chi-squared test results were used to
compare categorical variables. Linear regression
models (univariate and stepwise multivariate) were
used to assess the relationship among variables,
including COPD, and myocardial fibrosis, measured
using ECV. Cox regression analyses (univariate and
backward stepwise multivariate with a p value of 0.05
for entry and 0.10 for removal) were used to evaluate
the relationships between myocardial fibrosis,
measured using ECV, and each of the outcomes in
patients with COPD, stratified by site. For the time to
hospitalizations for HF analyses, dying patients were
censored at the time point of their death. For con-
sistency between sites, duration of follow-up for
UPMC patients was censored at 1,537 days, which was
the longest follow-up duration for MFT patients. The
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models satisfied the global Schoenfeld test for pro-
portional hazards. The plots of the individual covar-
iate scaled Schoenfeld residuals against time also
demonstrated no evidence of a relationship with time
(Supplemental Figure 1). The p value for ECV was
borderline (0.05); however, it was preferable to fit a
common time effect for ECV for simplicity, and tests
of continuous covariate linearity further showed the
inclusion of unadjusted ECV. ECV did not interact
with the other variables used in the regression
models. Wald tests for model coefficients using the
chi-squared distribution were used as an indication of
the strength of relationships between variables and
outcome. Kaplan-Meier curves used the log-rank test
with ECV categorized below and above the median.
Generalized estimating equations were used to
compare USPIO-related change in magnetic relaxa-
tion rates over time (10). Briefly, analyses were con-
ducted using a robust estimator covariance matrix
and an exchangeable working correlation matrix. A
hybrid parameter estimation method was used with
maximum-likelihood estimate for the scale parameter
method. Correlation analysis was performed using
Pearson or Spearman test correlation as appropriate.
Statistical analyses were performed using SPSS
version 22 software (IBM, Armonk, New York).
RESULTS
RELATIONSHIP BETWEEN COPD AND MYOCARDIAL
FIBROSIS. The cohort consisted of 572 patients,
including 450 patients with COPD and 122 randomly
selected age- and sex-matched patients without
COPD. Baseline characteristics are summarized in
Table 1, Supplemental Results, and Supplemental
Tables 1 and 2. Pulmonary function tests were avail-
able in 235 patients with COPD. Mean FEV1 was 67.6%
 21.1%. COPD was associated with a higher burden of
myocardial fibrosis (median ECV: 28.0% [IQR: 25.8%
to 31.1%] vs. 26.1% [IQR: 23.7% to 28.8%; p < 0.001).
Current smoking, ever smoking (defined as current or
previous smoking), and diabetes mellitus were more
common in patients with COPD. COPD was associated
with lower LV ejection fraction (55% [44% to 65%] vs.
60% [51% to 70%], respectively; p < 0.001) and RV
ejection fraction (56% [49% to 63%] vs. 62% [55% to
66%], respectively; p < 0.001).
Univariate and multivariate associations with
myocardial fibrosis are displayed in Table 2. In
multivariate analysis, COPD was independently
associated with myocardial fibrosis (unstandardized
coefficient B: 1.15; SE: 0.35; p ¼ 0.001).
RELATIONSHIP BETWEEN MYOCARDIAL FIBROSIS
AND OUTCOME IN COPD. The cohort consisted of thesame 450 patients with COPD. During a median
follow-up period of 726 days (interquartile range: 492
to 1,160 days), 101 patients were either hospitalized
for HF or died. Thirty-six patients were hospitalized
for HF, and 77 patients died. No patient was lost to
follow-up.
In multivariate Cox regression analysis, myocardial
fibrosis was independently associated with the com-
posite primary outcome of hospitalization for HF or
all-cause mortality (hazard ratio [HR] per 1% increase
in ECV: 1.14; 95% confidence interval (CI): 1.08 to
1.20; p < 0.001) (Table 3, Central Illustration), hospi-
talizations for HF (HR: 1.25; 95% CI: 1.14 to 1.36;
p < 0.001) (Table 3, Figure 1), and all-cause mortality
(HR: 1.13; 95% CI: 1.06 to 1.19; p < 0.001) (Supple-
mental Table 3, Supplemental Figure 2). Myocardial
fibrosis was more strongly associated with each of the
outcomes than any other variable. Substituting ECV
for native myocardial T1 (longitudinal relaxation
time) or post-contrast myocardial T1 revealed that
neither were associated with the primary outcome
(Supplemental Tables 4 and 5).
When FEV1 was included in the multivariate Cox
regression model, myocardial fibrosis was the only
variable independently associated with the compos-
ite outcome of hospitalization for HF or all-cause
mortality (HR: 1.15; 95% CI: 1.06 to 1.25; p < 0.001)
(Supplemental Table 6). Similarly, myocardial fibrosis
remained independently associated with the com-
posite outcome when RV ejection fraction was
included in the model (Supplemental Table 7).
RELATIONSHIP BETWEEN COPD AND MYOCARDIAL
INFLAMMATION. The study consisted of 15 patients
with an acute respiratory exacerbation of COPD. Pa-
tient characteristics are summarized in Supplemental
Table 8. The acute evaluation was performed at a
median of 16 days (15 to 20 days) after exacerbation
onset. Ten patients returned for the stable evalua-
tion, which was performed at a median of 119 days
(102 to 140 days) after exacerbation onset. The rea-
sons for not returning for the stable evaluation were:
claustrophobia (2 patients), breathlessness (1 pa-
tient), mild reaction to USPIO (1 patient), and clinical
deterioration (1 patient). According to an FEV1 mea-
surement performed at the stable evaluation, 1 pa-
tient (10%) had mild COPD, 7 (70%) had moderate
COPD, and 2 (20%) had severe COPD. Fifteen healthy
volunteers were recruited (Supplemental Table 8).
Acute COPD was associated with elevated C-reac-
tive protein and white cell counts, which were lower
in patients with stable COPD but did not return to
normal (Supplemental Table 9). Two patients
demonstrated evidence of chronic myocardial
TABLE 3 Cox Regression Modeling of the Combined Endpoint (Hospitalization for Heart Failure or All-Cause Mortality) and of Hospitalization for
Heart Failure Alone
Combined End Point
Univariate Model (n ¼ 450) Multivariate model (n ¼ 392)||
Chi-Square Test HR (95% CI) p Value Chi-Square Test HR (95% CI) p Value
Demographics
Age (per 1 yr increase) 0.46 1.01 (0.99 to 1.03) 0.499
Male 1.59 1.31 (0.86 to 2.00) 0.207
BSA (per 0.01 m2 increase) 1.12 1.00 (1.00 to 1.01) 0.289
Comorbidities
Current Smoker 0.72 1.20 (0.79 to 1.80) 0.395
Ever Smoker 0.76 1.32 (0.71 to 2.47) 0.384
Diabetes mellitus 3.74 1.50 (1.00 to 2.27) 0.053
Hypertension 3.06 1.44 (0.96 to 2.15) 0.080
Dyslipidemia 2.94 0.71 (0.48 to 1.05) 0.086
Atrial fibrillation 1.41 1.33 (0.83 to 2.14) 0.236
Coronary revascularizations 3.52 1.49 (0.98 to 2.27) 0.061 10.24 2.13 (1.34 to 3.38) 0.001
Laboratory and CMR findings
LV EF (per 1% increase)* 10.26 0.98 (0.97 to 0.99) 0.001
LV mass (per 1 g/m2 increase)* 6.71 1.01 (1.00 to 1.02) 0.010 7.67 1.01 (1.00 to 1.02) 0.006
MI present† 5.27 1.60 (1.07 to 2.39) 0.022
ECV (per 1% increase)‡ 30.45 1.15 (1.09 to 1.21) <0.001 23.76 1.14 (1.08 to 1.20) <0.001
eGFR§ 3.65 0.99 (0.98 to 1.00) 0.056
Hematocrit (per 1% increase)† 18.42 0.93 (0.90 to 0.96) <0.001
TABLE 3 Continued
Hospitalization for Heart Failure
Univariate Model (n ¼ 450) Multivariate Model (n ¼ 392)||
Chi-Square Test HR (95% CI) p Value Chi-Square Test HR (95% CI) p Value
Demographics
Age (per 1 yr increase) 0.05 1.00 (0.97–1.03) 0.819
Male 0.20 0.86 (0.44 to 1.03) 0.655 5.49 0.34 (0.14 to 0.84) 0.019
BSA (per 0.01 m2 increase) 2.00 1.01 (1.00 to 1.02) 0.157 9.17 1.02 (1.01 to 1.04) 0.002
Comorbidities
Current Smoker 0.02 1.05 (0.52 to 2.11) 0.896
Ever Smoker 0.01 0.97 (0.38 to 2.49) 0.944
Diabetes mellitus 4.85 2.11 (1.09 to 4.09) 0.028 5.08 2.33 (1.12 to 4.86) 0.024
Hypertension 2.20 1.69 (0.84 to 3.40) 0.138
Dyslipidemia 0.19 0.87 (0.45 to 1.67) 0.667
Atrial fibrillation 0.01 0.96 (0.40 to 2.30) 0.922
Coronary revascularizations 0.04 0.92 (0.42 to 2.02) 0.838
Laboratory and CMR findings
LV EF (per 1% increase)* 11.95 0.97 (0.95 to 0.99) 0.001
LV mass (per 1 g/m2 increase)* 14.42 1.02 (1.01 to 1.03) <0.001 14.82 1.03 (1.01–1.04) <0.001
MI present† 1.41 1.51 (0.77 to 2.97) 0.235
ECV (per 1% increase)‡ 27.99 1.23 (1.14 to 1.33) <0.001 24.88 1.25 (1.14 to 1.36) <0.001
eGFR§ 1.93 0.99 (0.97 to 1.01) 0.164
Hematocrit (per 1% increase)† 9.31 0.92 (0.87 to 0.97) 0.002
*n ¼ 435; †n ¼ 425; ‡n ¼ 393; §n ¼ 449, per 1 ml/min per 1.73 m2 increase; ||stepwise model was performed in 392 patients with complete data.
CI ¼ confidence interval; CMR ¼ cardiac magnetic resonance; HR ¼ hazard ratio; other abbreviations as in Tables 1 and 2.
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infarction on late enhanced imaging that was other-
wise unrecognized clinically. Infarcted myocardium
was excluded from all parametric analyses.
USPIO-CMR demonstrated evidence of myocardial
inflammation in COPD at both the acute and stabletime points (Supplemental Tables 9 and 10, Figure 2).
Myocardial R2* behavior over time (p ¼ 0.038) and
R2*:R1 ratio (p ¼ 0.005) were significantly higher in
acute COPD patients than in healthy volunteers, and
in stable patients with COPD than in healthy
CENTRAL ILLUSTRATION Myocardial Fibrosis and












































Above Median ECV Below Median ECV
Lagan, J. et al. J Am Coll Cardiol Img. 2021;-(-):-–-.
Kaplan-Meier curve for survival free from a composite of all-cause mortality or hospi-
talization for heart failure (HHF) in patients with chronic obstructive pulmonary disease,
according to myocardial fibrosis burden. Myocardial fibrosis was measured using cardiac
magnetic resonance extracellular volume (ECV).
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volunteers (p ¼ 0.005 and p ¼ 0.025, respectively).
There were no significant differences between acute
and stable COPD. Indicators of myocardial edema
were inconsistent; there were no differences in
myocardial T2 relaxation time between acute and
stable COPD, although myocardial T1 was higher
during the acute than during the stable period.
Myocardial capillary permeability was numerically
higher during acute COPD, but the differences were
not statistically significant.
RELATIONSHIP BETWEEN SMOKING AND MYOCARDIAL
INFLAMMATION. The study consisted of 15 current
smokers. Participant characteristics are summarized
in Supplemental Table 8. Smokers demonstrated
intermediate USPIO-CMR measurements that were
between those from healthy volunteers and those
with COPD (Figure 2). Myocardial R2* behavior over
time (p ¼ 0.015) (Supplemental Table 10) was signifi-
cantly higher in smokers than in healthy volunteers
but differences in R2*:R1 ratios were not statistically
significant (Supplemental Table 9, Figure 2). There
was no evidence of myocardial edema or increased
capillary permeability.
There were significant relationships between the
severity of myocardial inflammation and biochemical
evidence of myocardial injury (correlation of
myocardial R2*:R1 ratio with circulating high-
sensitivity troponin I; r ¼ 0.56; p ¼ 0.004) and
severity of airflow limitation (correlation of myocar-
dial R2*:R1 ratio with FEV1 r ¼ 0.50; p ¼ 0.010) in
stable COPD and smokers.
DISCUSSION
This study found COPD was associated with
myocardial fibrosis, independent of demographics,
comorbidities, and other cardiac structural and
functional factors. Furthermore, in patients with
COPD, myocardial fibrosis was independently pre-
dictive of hospitalization for HF and death. The study
also showed COPD to be associated with myocardial
inflammation. These findings provide, for the first
time, potential evidence for a pathophysiological
mechanism underlying the association between COPD
and HF.
The reported prevalence of HF in patients with
COPD ranges between approximately 7% and 31%, but
the broad “type” of HF with which COPD associates
(i.e., reduced vs. preserved ejection fraction [EF]) has
been poorly characterized (11). In the current study,
COPD was associated with lower LVEF than matched
patients without COPD, but in most of the patients,
LVEF was within the accepted normal range or at
most mildly reduced, and LVEF was notindependently associated with hospitalization for HF
or death, thus suggesting that the predominant type
of HF associated with COPD is HF with preserved EF.
Although large epidemiological studies have
demonstrated that the association between COPD and
HF is independent of common risk factors such as
ischemic heart disease, diabetes, and hypertension,
the mechanism responsible for the association has
remained unclear (1). Myocardial fibrosis, driven by
myocardial inflammation occurring as part of systemic
inflammation leading to mechanical, electric, and
vasomotor dysfunction of the myocardium is a widely
held hypothesis (2). Indirect evidence for the hypoth-
esis includes the association of circulating inflamma-
tory and fibrotic biomarkers with LV diastolic
dysfunction and incident HF and with airflow limita-
tion in patientswith COPD, but there has been no direct
evidence (3,12–15). Othermechanisms, such as reduced
LV preload secondary to pulmonary dysfunction,
increased afterload due to arterial stiffness, and auto-
nomic dysfunction, have also been proposed (3,4).
FIGURE 1 Myocardial Fibrosis and Survival Free From Hospitalization for Heart Failure
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Kaplan-Meier curve for survival free from hospitalization for heart failure in patients with
chronic obstructive pulmonary disease, according to myocardial fibrosis burden.
Myocardial fibrosis was measured using cardiac magnetic resonance extracellular volume
(ECV).
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Post mortem studies and a small previous cardiac
CMR study have previously demonstrated evidence
of myocardial fibrosis in COPD (16,17). However, those
studies were confounded by comorbidities that are
frequent in patients with COPD and are themselves
associated with myocardial fibrosis. The large sample
size of the current study means that, for the first time,
COPD per se has been shown to be independently
associated with myocardial fibrosis. Crucially, this
study also shows that myocardial fibrosis is inde-
pendently associated with hospitalization for HF and
death in patients with COPD. Indeed, myocardial
fibrosis was the strongest predictor of adverse
outcome, outperforming comorbidities, traditional
cardiac indices, and the key spirometry COPD index,
FEV1.
These novel findings have important implications
for the clinical management of patients with COPD
and future research. Risk stratification in cases of
COPD is imprecise, and prognostic models are poorly
discriminative (18). The unparalleled risk stratifica-
tion provided by the burden of myocardial fibrosis in
the current study means that this measurement could
be considered in the prognostication of patients with
COPD. Furthermore, trials of therapeutics that targetmyocardial fibrosis, with the aim of improving the
outcome of patients with COPD, are warranted.
Elevated circulating troponin levels are observed
in acutely exacerbating and chronic stable COPD, the
magnitude of which in the latter is associated with
the severity of airflow obstruction and circulating
markers of immune activation (13,19). Myocardial
inflammation-induced cardiomyocyte injury has been
proposed as a possible mechanism, but evidence for
this has been lacking. The current study demon-
strates, for the first time, that both acutely exacer-
bating and stable COPD are associated with
myocardial inflammation in the form of myocardial
macrophage infiltration. Indeed, in keeping with the
aforementioned circulating biomarker studies, the
magnitude of myocardial inflammation in the current
study was associated with severity of airflow
obstruction and circulating troponin levels. USPIO-
CMR was used due to its specificity for myocardial
inflammation. Circulating inflammatory biomarkers
are not specific to the myocardium and standard
cardiac CMR techniques and fluorine-18-labeled flu-
orodeoxyglucose positron emission tomography are
not specific for inflammation.
Acute exacerbation of COPD is associated with
greater systemic inflammation than stable COPD, and
circulating troponin levels are generally higher dur-
ing acute exacerbation, although comparative
troponin data are limited, and the differences may be
due to nebulized beta-2-agonist-induced tachycardia
in the acute phase (13,20,21). In the current study, the
severity of myocardial inflammation observed during
acute exacerbation was similar to that in the stable
period. More severe myocardial inflammation may
have been evident if the CMR scan had been under-
taken closer to the onset of the exacerbation (the in-
terval was 16 days), but patient breathlessness
prevented it from being performed earlier (Supple-
mental Appendix).
Although the present study elucidates a potential
pathophysiological mechanism underlying the asso-
ciation between COPD and HF, it does not establish
causality, and further studies are required.
STUDY LIMITATIONS. Participants in Part 1 under-
went clinical cardiac CMR scanning; thus, they might
not be representative of a more general COPD popu-
lation. Spirometric data were not available for 48% of
patients with COPD, thus it is possible that, despite
their clinical diagnoses, some patients might not have
had COPD. Nevertheless, despite this potential null
bias that might have reduced the likelihood of
detecting associations, significant associations were
identified. CMR analysis was performed blinded to
FIGURE 2 USPIO-Enhanced CMR Measurements in Patients With COPD During Acute Exacerbation (Acute COPD) and When Stable (Stable
























Acute COPD Stable COPD
Healthy Smokers
Acute COPD Stable COPD
(A) Myocardial R2*. (B) Myocardial R2*/R1 ratio. Scan 1 ¼ baseline CMR scan before USPIO administration. Scans 2 and scan 3 ¼ CMR scans
performed at 48 and 72 hours, respectively, following USPIO administration. CMR ¼ cardiac magnetic resonance; COPD ¼ chronic obstructive
pulmonary disease; USPIO ¼ ultrasmall superparamagnetic particles of iron oxide.
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outcome data but was not blinded to the presence or
absence of COPD, which could introduce bias. Rea-
sons for hospitalization were determined by the
clinical team responsible for patients’ care. Differen-
tiating between hospitalization due to HF and hos-
pitalization due to COPD exacerbation can be
challenging, but with the full clinical information
available, the clinical teams are well placed to make
this differentiation (22), and it is the clinical team that
determines how the patient is managed. Further-
more, the clinical team was independent of the
research team. Patients were scanned using 3 scan-
ners, at 2 magnetic field strengths, in 2 centers, which
could introduce variability. Nevertheless, the associ-
ation between ECV and outcome was demonstrated
despite this. Although the relationship between ECV
and histological myocardial fibrosis has been
demonstrated in a number of previous studies, his-
tological validation was not performed in the current
study, and the relationship between ECV and histo-
logical myocardial fibrosis demonstrated in the pre-
vious studies may not necessarily extrapolate to the
current study (6,7). In Part 2, patients with COPD were
older than current smokers; thus, it was not possible
to simultaneously match ages of healthy volunteers
to both groups. However, the impact of age on
myocardial T2* and T1 is minimal, and patients with
COPD served as their own controls for the acute and
stable comparisons (23–27). Sample size was smaller
than in Part 1, although important between-group
differences were identified. The possible impact of
the timing of the acute CMR is discussed above.USPIO are phagocytosed by active cardiac macro-
phages, which are widely considered to be part of
tissue inflammatory response, but they are not spe-
cific to the initiating injury. Thus, this study is unable
to determine the cause of the inflammatory response.
CONCLUSIONS
The associations among COPD, myocardial inflamma-
tion and myocardial fibrosis, and the independent
prognostic value of myocardial fibrosis elucidate a
potential pathophysiological link between COPD and
HF. The findings have the potential to improve patient
risk stratification and to be the basis for developing
new therapeutic strategies for patients with COPD.
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